

BUSINESS OVERVIEW

- CORE BUSINESS:** Hexagon Nutrition is a research-driven, pure-play nutrition company that provides specialized health solutions across clinical nutrition, micronutrient premixes, and therapeutic products
- SCALE:** The company has a global presence in over 80 countries and operates 4 manufacturing facilities, including one overseas in Uzbekistan
- PROMOTER:** Led by Mr. Vikram A. Kelkar (Managing Director) holding 23.45% shares & Mr. Arun P. Kelkar (Chairman) holding 22.01% shares.
- MARKET:** The global nutrition industry is moving toward personalized health and fortified foods as consumers seek to manage age-related and lifestyle diseases. Hexagon is capturing this growth by expanding into emerging economies across Africa, the Middle East, and Asia, where there is high demand for affordable, science-backed nutrition

EPS: ₹1.57

ROCE: 17.06%

KEY HIGHLIGHTS

- SECTOR TAILWINDS:** Rising disposable incomes and Indian government support through the National Nutrition Mission are driving a massive shift toward preventive healthcare. This positive trend is reflected in the company's internal growth, with branded product sales jumping 29.9% and export premix sales rising by 19% this year
- IPO PLANS:** The company filed DRHP in Sept 2025 and received SEBI approval in Feb 2026 for an IPO consisting of a 100% Offer for Sale by existing promoters and group members, with no fresh issue component.
- STRATEGIC OUTLOOK:** By 2030, the company aims to lead in vitamin innovation and scale up food fortification to reach over 200 staple producers across Africa, the Middle East, and Asia, This growth is being further accelerated through pan-India omnichannel distribution, including major e-commerce platforms and specialized nutrition websites

FINANCIAL PERFORMANCE

Particulars	FY 2024-25	FY 2023-24	Growth %
REVENUE FROM OPERATIONS	₹324.93 Cr	₹297.73 Cr	9.14%
EBITDA	₹40.07 Cr	₹24.88 Cr	61.06%
PAT	₹24.31 Cr	₹12.29 Cr	97.78%
NET WORTH	₹194.18 Cr	₹175.95 Cr	10.36%

CORPORATE ACTION

- AMALGAMATION:** Filed an application with the NCLT in May 2025 for the merger of its export subsidiary into the parent company.
- INVESTOR EXIT:** Somerset Indus Healthcare Fund I Limited, a long-term private equity investor, exited the company in 2025.
- DIVIDENDS:** Paid an interim dividend of ₹4.10 per share (41%) to preference shareholders, while choosing not to pay equity dividends to preserve cash for growth and capital expenditure